

Product Datasheet

AZD4604

Catalog No. **BP-01993** · CAS **2241039-81-4** · Form **free base** · Physical state **solid** · Color **White to off-white** · Version **1.0** · Revision **2026-09-10**


FOR RESEARCH USE ONLY. NOT FOR HUMAN OR VETERINARY USE.

Target JAK	Research area Inflammation/Immunology
----------------------	---

Molecular formula **C₂₈H₃₁F₂N₇O₄S**

Molecular weight **599.6520**

STRUCTURE



DESCRIPTION

AZD4604 is a Janus-associated kinase 1 (JAK1) inhibitor extracted from patent WO2018134213A1, Example 63, has an anti-inflammatory effect.

BIOLOGICAL ACTIVITY

In Vitro

Londamocitinib inhibits the phosphorylation of STAT6 in U937 cells induced by IL-4 or IL-13 (IC₅₀ are 24 and 34 nM, respectively).

In Vivo

Londamocitinib (1 mg/kg, intravenous injection, single dose) can reduce the phosphorylation of STAT3 and STAT5 in the lung of obumin-induced asthmatic rats, inhibit pulmonary eosinophilia, and reduce advanced asthma response in the same model.

SOLUBILITY

Soluble in DMSO 71.43 mg/mL

REFERENCES

- [1]. NILSSON, Karl, Magnus, et al. Jak1 selective inhibitors. WO2018134213A1.
- [2]. Nilsson M, et al. Discovery of the Potent and Selective Inhaled Janus Kinase 1 Inhibitor AZD4604 and Its Preclinical Characterization. J Med Chem. 2023 Oct 12;66(19):13400-13415.
- [3]. Nilsson M, et al. Characterization of Selective and Potent JAK1 Inhibitors Intended for the Inhaled Treatment of Asthma. Drug Des Devel Ther. 2022 Aug 31;16:2901-2917.

Tel: +86 20 31130026 · Fax: +86 20 36822386 · tech@biochemprobe.com · www.biochemprobe.com

BiochemProbe is the catalog brand of Guangzhou Yuyuan Biotech Co., Ltd. · For research use only.

Lot CoA and SDS are separate documents.